Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS

This is a single-arm pilot study of the feasibility and safety of metformin in patients with clonal cytopenia of undetermined significance (CCUS) or lower-risk myelodysplastic neoplasms (LR-MDS).

Trial Details

NCT ID
NCT04741945
Phase
PHASE2
Sponsor
Kirsten Grønbæk
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Metformin
Locations (sample)
  • Copenhagen, Copenhagen N, Denmark|55.67594,12.56553

Key Eligibility Criteria

  • A diagnosis of:
  • LR-MDS according to the revised international prognostic scoring system (IPSS-R), i.e., very low- or low-risk disease (IPSS-R score ≤3) in addition…
  • CCUS defined as the presence of somatic mutation(s) or cytogenetic abnormality not diagnostic of MDS or any other malignancy in the context of pers…
  • Menopause, if being a female, defined as females \>45 years of age who have experienced amenorrhea for minimum 12 months, without any other obvious…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →